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Why it Is ImportantValentin Fuster, MD, PHDO ver the course of the past month in theJournal, we have published a 4-part serieson statistics for clinical trials from Profes-
sor Stuart Pocock and his colleagues, which included
“Making Sense of Statistics in Clinical Trial Reports”
(1), “Statistical Controversies in Reporting of Clinical
Trials” (2), “Design of Major Randomized Trials” (3),
and “Challenging Issues in Clinical Trial Design” (4).
I have been most impressed with the clarity with
which Pocock et al. (1–4) communicated the chal-
lenges and presented recommendations on these
complex topics. In my opinion, this is a must-read
series for all of us who are engaged in caring for pa-
tients, reading the literature, and conducting clinical
trials in the ﬁeld of cardiovascular medicine. We have
been so encouraged by the outcome of this statistics
series that the JACC board and I have decided to
select several additional timely topics and have those
areas of interest explicated across 4 successive papers
in forthcoming issues of the Journal.
I initially commissioned this series to appear in
4 sequential issues as a response to widespread
confusion among the clinical community with regard
to statistics in the design and presentation of clinical
trials. We have published this series with the hope of
informing and creating a dialogue for improvement
among the clinical community. For instance, there
has been an obsessive focus on p values in recent
years. Yet, p values can be grossly misinterpreted. As
an example, a p value that may be very signiﬁcant in a
study with a large population or a meta-analysis may
not represent a clinically important effect when
treating patients in our daily lives. As another. Wiener Cardiovascular Institute, Icahn
inai, New York, New York.example, authors often present the relative risk
rather that the absolute risk difference, the latter of
which has more value to patients. Thus, the decrease
of an event rate from 4% to 2% is often reported as a
50% decrease, which is the relative risk reduction, but
the absolute decrease is 2%. To overcome some of
these challenges, it is tremendously important that
the statistician, writers, and researchers of a trial
maintain a close relationship throughout the process.
Some of the considerations with the presentation
of statistics recently became apparent through the
publication of SPRINT (Systolic Blood Pressure
Intervention Trial) in the New England Journal of
Medicine (5). This landmark trial will have a wide-
spread effect on increasing the use of blood pressure–
lowering medications in the general population.
Thus, in interpreting the trial’s ﬁndings, it is impor-
tant to consider both relative and absolute risk
differences for both efﬁcacy and safety outcomes in a
consistent manner. For instance, in the discussion
section, the authors wrote: “Trial participants
assigned to the lower systolic blood-pressure target
(intensive-treatment group), as compared with those
assigned to the higher target (standard-treatment
group), had a 25% lower relative risk of the primary
outcome” (5) (italics in quotation marks included for
emphasis). In actuality, this is an absolute risk
reduction of 5.2% versus 6.8% patients with a
primary outcome over a median 3.26-year follow-up.
However, in our charge as investigators to assess
both the safety and efﬁcacy of therapies for our pa-
tients, we need to be very clear when presenting
adverse outcomes. When reporting on the serious
adverse events, the authors wrote that 4.7% of the
intensive-treatment group and 2.5% of the standard-
treatment group had serious adverse events that
were classiﬁed as possibly or deﬁnitely related to the
TABLE 1 Generalizability of U.S. Population, Including All
Patients Treated or Untreated With Hypertension, Using the
SPRINT Eligibility Criteria
Population Number in Millions
Percent (95% CI)
SPRINT Eligible
All U.S. adults 219.4 7.6 (7.0-8.3)
Hypertension 68.5 20.0 (18.6-21.5)
Treated hypertension 49.2 16.7 (15.2-18.3)
The percentage of U.S. adults who meet the eligibility criteria for SPRINT. Data
from Bress et al. (7).
CI ¼ conﬁdence interval; SPRINT ¼ Systolic Blood Pressure Intervention Trial.
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2910intervention (5), which is a relative risk increase of
88%. Also, the authors reported an important excess
risk of acute kidney injury or acute renal failure in the
intensive group: 4.4% versus 2.6% patients affected,
which is a relative risk increase of 71%. This trade-off
between efﬁcacy and safety (beneﬁts and risks) is
essential in achieving cautious balanced conclusions
from this trial.
Importantly, the SPRINT trial’s patient population
deserves attention as well. The investigators
excluded anyone younger than 50 years of age, as
well as patients with prior stroke (5). In addition, they
excluded diabetic patients—a population that
comprised 29.1 million Americans in 2012, or nearly
10% of the U.S. population (6). Thus, we, as clinicians,
have to be particularly cautious when interpreting
these results in the overall hypertension population,
because the patients included in this study are 20% of
our actual hypertensive patients seen in practice
(Table 1) (7). Nevertheless, these comments are in no
way an attempt to discount the importance of
the SPRINT trial that was conducted with the
highest degree of standards and which will have an
effect in treating hypertension. I am simply attempt-
ing to call attention to the delicacy of presenting
statistics.
In conclusion, it is our responsibility as clinicians
and investigators to carefully conduct trials and
communicate those data in a straightforward and
precise manner. To do that, statisticians andmanuscript authors need to maintain a close-knit
relationship throughout the process to ensure align-
ment in the interpretation and presentation of the
data. In addition, it is important that the cardiovas-
cular research community develop practical stan-
dards and similar language around this process. We
truly hope that the 4-part review series by Pocock
et al. (1–4) has helped to contribute to the published
data, and more importantly, that it becomes a useful
companion to the community’s paper writing and to
clinicians’ understanding of published reports.
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